key: cord-1019804-g3iczwue
authors: Nörz, D.; Grunwald, M.; Olearo, F.; Fischer, N.; Aepfelbacher, M.; Pfefferle, S.; Lütgehetmann, M.
title: Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with build-in screening functionality for DelHV69/70- and N501Y variants such as B.1.1.7
date: 2021-02-18
journal: nan
DOI: 10.1101/2021.02.12.21251614
sha: 125a3e8ce28c90a68af2a96b701975498da2824f
doc_id: 1019804
cord_uid: g3iczwue

Background: New SARS-CoV-2 variants with increased transmissibility, like B.1.1.7 from England or B1.351 from South Africa, have caused considerable concern worldwide. In order to contain the spread of these lineages, it is of utmost importance to have rapid, sensitive and high-throughput detection methods at hand. Methods: Analytical sensitivity was assessed for both wild-type SARS-CoV-2 and B.1.1.7 lineage by serial dilution. A total of 141 clinical samples were subjected to the test and results compared to a commercial manual typing-PCR assay and NGS. Results: The multiplex assay is highly sensitive for detection of SARS-CoV-2 RNA in clinical samples, with an LoD of 25.82 cp/ml (CI: 11.61 - 57.48). LoDs are slightly higher for the HV68/70 deletion (111.36 cp/ml; CI: 78.16 - 158.67) and the N501Y SNP (2548.04 cp/ml, CI: 1592.58 - 4076.73). A total of 141 clinical samples were tested with the assay, including 16 samples containing SARS-CoV-2 of the B.1.1.7 lineage. Three non-B.1.1.7 samples contained a HV69/70 deletion. All were correctly identified by the multiplex assay. Conclusion: We describe here a highly sensitive, fully automated multiplex PCR assay for the simultaneous detection of del-HV69/70 and N501Y that can distinguish between lineages B.1.1.7 and B1.351. The assay allows for high-throughput screening for relevant variants in clinical samples prior to sequencing.

England or B1.351 from South Africa, have caused considerable concern worldwide. In order 35 to contain the spread of these lineages, it is of utmost importance to have rapid, sensitive and 36 high-throughput detection methods at hand. Methods: Analytical sensitivity was assessed for 37 both wild-type SARS-CoV-2 and B.1.1.7 lineage by serial dilution. A total of 141 clinical samples 38 were subjected to the test and results compared to a commercial manual typing-PCR assay 39 and NGS. Results: The multiplex assay is highly sensitive for detection of SARS-CoV-2 RNA in 40 clinical samples, with an LoD of 25.82 cp/ml As a result of increased awareness in public health and science institutions, there has been a 63 rapidly growing demand for whole genome sequencing worldwide in order to recognize and 64 map the spread of these emerging variants. In this context, the speed and scalability of fully 65 automated RT-PCR can be highly beneficial to pre-screen samples for relevant mutations. 66 The aim of this study was to create and validate a high-throughput first-line screening assay The basic rationale of the multiplex assay was to combine two highly sensitive diagnostic SARS-CoV-2 74 PCR assays with additional assays to simultaneously detect relevant mutations. The SC2-assay by the 75 US CDC (N-gene, SC2-N) was modified to serve as Pan-SCoV2 target (9). A publicly available diagnostic 76 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 18, 2021. ; https://doi.org/10.1101/2021.02.12.21251614 doi: medRxiv preprint S-gene assay by Zhen et al. serves as second target (SC2-S) (10), while also featuring a drop-out 77 phenomenon in the presence of a HV69/70 deletion due to probe location, which is rescued by an 78 additional Taqman-probe (S-Del) that allows differentiation for wild-type and del-HV69/70. An 79 additional assay was designed (using Beacon designer and PrimerQuest software) and integrated into 80 the multiplex to detect the N501Y SNP. See Figure 1 for a schematic overview of the PCRs and their 81 target regions. 82 83 84 85 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 18, 2021. ; https://doi.org/10.1101/2021.02.12.21251614 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in lineage (according to SARS CoV-2 whole genome sequencing) were used to prepare dilution series in 132 pooled negative patient samples. Absolute quantification of the latter was carried out using the same 133 assay with preexisting linearity data and the Accuplex verification panel as reference on the cobas6800 134 system (11). 2-fold dilution series (8 repeats per dilution step) were used to determine lower limit of 135 detection. 136 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 To evaluate clinical performance and specificity of differentiation, a set of 101 samples RT-PCR positive 137 for SARS-CoV-2 were subjected to the SCOV2_VAR_UCT. Of these samples, 14 were predetermined as 138 B.1.1.7 lineage. Presence of the respective mutations was confirmed by a set of commercial assays by 139 TIB MOL (VirSNiP Spike N501Y and Del69/70, Berlin, Germany). Presence of del-HV69/70 and N501Y 140 mutations in the non-B117 set was precluded using the same commercial assays. A further 40 SARS-141

CoV-2 negative samples (by cobas SARS-CoV-2 IVD test), and a cross-reactivity panel containing various 142 respiratory pathogens (supplementary table 1) were tested with the assay to assess overall specificity. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in inclusivity issues of commercial assays such as the "TaqPath RT-PCR COVID-19 kit" (Thermo Fischer 175 Scientific, USA) can coincidentally be used to pre-screen for B.1.1.7 lineage variants because of a drop-176 out phenomenon in one of the targets associated with del-HV69/70 (12). However, this method runs 177 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in In conclusion, the SCOV2_VAR_UCT multiplex presented in this study combines highly sensitive SARS-189

CoV-2 detection with relatively reliable identification of the B.1.1.7 lineage by detecting two hallmark 190 mutations. Furthermore, other lineages featuring the N501Y SNP, but lacking the deletion, would also 191 be recognized as abnormal for further investigation. It can thus be used either as a secondary assay for 192 pre-screening prior to sequencing, or as a first-line diagnostic assay. Using the cobas6800/8800 193 automated systems, this setup can be employed for high-throughput screening for B.1.1.7 and other 194 variants, requiring minimal hands-on time. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 18, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

ML received speaker honoraria and related travel expenses from Roche Diagnostics

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody 211 Neutralization

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from 217 linking epidemiological and genetic data

Recurrent emergence 220 and transmission of a SARS-CoV-2 Spike deletion H69/V70

Molecular Mechanism of the N501Y Mutation for Enhanced 223 Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 232 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch 236 during 48 hours in the midst of the COVID-19 pandemic

Evaluation of a quantitative RT-PCR 239 assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput 240 system

Research Use Only CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay Real-Time 242 RT-PCR Primers and Probes. CDC Website

Development of a New Multiplex Real-Time RT-PCR Assay for Severe 244

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. The Journal of molecular 245 diagnostics

Pushing beyond specifications: Evaluation of linearity and clinical 248 performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in blood 249 and other materials outside recommendations

Two-step strategy for the identification of SARS-CoV-2 variant of 254 concern 202012/01 and other variants with spike deletion H69-V70, France